Besides its properties of decreasing intraocular pressure, timolol is preferred in the treatment of glaucoma because it:
The options aren't provided, but the correct answer is likely about another benefit. Beta-blockers like timolol have systemic effects, but in the eye, they're topically administered to avoid systemic side effects. Wait, maybe it's about not increasing heart rate? Or perhaps its beta-1 selectivity? No, timolol is non-selective. Wait, another angle: maybe it's about not causing systemic side effects because it's a beta-blocker with minimal systemic absorption when applied topically. That's a key point. So the reason could be that it has good efficacy with low systemic toxicity. Or maybe it's about being a first-line agent. Hmm.
Wait, another angle: some beta-blockers might have alpha-agonist properties, but timolol is a pure beta-blocker. Maybe it's about not causing rebound effects? Or maybe it's about being a non-selective beta-blocker which is better for glaucoma? No, non-selective might have more side effects. Wait, another thought: timolol has a longer duration of action, so once-daily dosing. But I'm not sure. Alternatively, maybe it's about not causing systemic hypotension. Wait, the question is why it's preferred besides lowering IOP. So the answer is likely related to its safety profile when used topically. Because systemic beta-blockers can have side effects, but topical application minimizes that. So the correct answer would be that it has minimal systemic absorption when used topically, making it safer. Let me confirm. Timolol is indeed a non-selective beta-blocker that's used topically in ophthalmic solutions. Because of the way it's administered, it doesn't enter the systemic circulation much, reducing side effects like bradycardia or hypotension. That's a key point. So the answer is probably that it has minimal systemic side effects due to topical application. Now, the wrong options might include things like increasing aqueous outflow (which is not how beta-blockers work), or promoting uveoscleral outflow (which is more for prostaglandin analogs), or maybe being a selective beta-1 blocker (but timolol is non-selective). So for each wrong option, I need to explain why they're incorrect. Let me structure the explanation accordingly.
**Core Concept**
Timolol, a non-selective beta-adrenergic antagonist, reduces intraocular pressure (IOP) in glaucoma by decreasing aqueous humor production. Its topical ophthalmic formulation minimizes systemic absorption and adverse effects, making it a preferred first-line therapy.
**Why the Correct Answer is Right**
The key advantage of timolol is its **minimal systemic absorption** when administered as eye drops. This is due to the corneal barrier and low lipid solubility, preventing significant entry into systemic circulation. Consequently, systemic side effects like bradycardia, hypotension, or bronchoconstriction are rare, making it safer for patients with comorbid